R&D The changing multiple sclerosis landscape: Earlier diagnosis... Multiple sclerosis (MS) is undergoing a meaningful evolution in how it is understood, diagnosed, and managed.
News New data build case for Roche's oral BTK drug for MS Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
News After phase 3 clean sweep, Roche plans oral BTK filing in MS Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?
News MSD and Mayo Clinic team up on AI drug discovery MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.
News Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
News NICE recommends wider use of MS drug natalizumab via NHS NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
